분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-04-10 08:57:54 , Hit : 2114
 Gilead seeks FDA OK for game-changing hepatitis C drug

Apr 8, 2013, 2:32pm PDT Updated: Apr 8, 2013, 2:51pm PDT
Drug development

Enlarge
John Martin is Gilead's chairman and CEO.


Ron Leuty
Reporter-
San Francisco Business Times

It could be the first company on the market with a once-a-day oral drug to combat chronic and potentially deadly hepatitis C.

The Foster City-based company (NASDAQ: GILD), long known for its portfolio of HIV/AIDS drugs, said Monday that it submitted a new drug application to the FDA to approve its experimental drug, called sofosbuvir.

Gilead, led by Chairman and CEO John Martin and President and COO John Milligan, got the drug in its $11 billion January 2011 acquisition of Pharmasset Inc. The company was criticized for the expensive move, but its subsequent clinical trials showed that sofosbuvir may eventually clear the body of the virus, vaulting Gilead into the lead in the race for a new, powerful, easy-to-take hepatitis C treatment.

"Current therapies are not suitable for large number of patients with (hepatitis C) infection and are challenging to take and tolerate," Martin said in a press release. "Sofosbuvir's antiviral potency, safety profile and once-daily administration have the potential to improve cure rates by simplifying and shortening therapy for patients with this disease."

Gilead's initial request is to sell the drug for patients who haven't been treated previously and have four specific types of hepatitis C, genotypes 1, 4, 5 and 6. At first, it would be used in combination with current treatments ribavirin and pegylated interferon, but Gilead officials have said that it eventually could be used in combination with other drugs that it is developing.

The drug, part of a new class of hepatitis C treatments, called "nucs," block a specific enzyme of the virus. It could be approved by the end of this year or early 2014.







727   임자 있는 초원들쥐가 외간들쥐를 거들떠보지도 않는 이유: 후성유전학  이성욱 2013/06/05 3279
726   면역시스템이 유익세균과 평화로운 공존을 유지하는 방법  이성욱 2013/05/28 2492
725   TNF를 이용한 안전한 항종양 치료법  이성욱 2013/05/28 2656
724   Viruses in the gut protect from infection  이성욱 2013/05/22 2907
723   황우석을 넘어서: 미국의 과학자들, 체세포복제 기술로 인간 배아줄기세포 제조 성공  이성욱 2013/05/17 2462
722   Janssen's experimental drug for hepatitis C gets FDA fast track  이성욱 2013/05/15 2828
721   세상을 바꿀 10가지 기술  이성욱 2013/05/13 2330
720   Most Europeans share recent ancestors  이성욱 2013/05/10 2156
719   약물 저항성 세균을 파괴하는 방법  이성욱 2013/05/10 2552
718   분자생물학의 거성(巨星) 떨어지다; 프랑수아 자콥의 삶과 업적  이성욱 2013/05/09 2833
717   FDA fast tracks AbbVie hepatitis C drug  이성욱 2013/05/08 2196
716   Targeted drugs to tackle hepatitis C  이성욱 2013/05/06 1798
715   DNA: Celebrate the unknowns  이성욱 2013/04/26 1972
714   Hepatitis C drug nears approval  이성욱 2013/04/24 2121
713   텔로머레이즈를 표적으로 삼는 새로운 항암 요법  이성욱 2013/04/24 3107
712   A pathogenic picornavirus acquires an envelope by hijacking cellular membranes  이성욱 2013/04/23 3003
711   BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal  이성욱 2013/04/17 2148
710   Scientists Map Elusive 3-D Structure of Telomerase Enzyme, Key Actor in Cancer, Aging  이성욱 2013/04/17 2305
  Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2114
708   'RNA sponge' mechanism may cause ALS/FTD neurodegeneration  이성욱 2013/04/02 2605

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN